Friday 6 November 2026 Export HALO’s income statement to Excel — free account

Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024.

Revenue: +39.2%
EPS: +45.6%
Free cash flow: −58.6%
Total debt: +115.1%

Quarter to September 2026, against a year earlier

105.08 17.88 −14.54%

Follow HALO

Alert me

Market cap: $14.0B
P/E: 29.5×
Fwd P/E: 17.9×
Dividend yield: —
F-score: 5/9
Altman Z: 3.46
Beneish M: −2.59
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Halozyme Therapeutics, Inc. (HALO) P/E ratio

Alert me on P/E ratio

As of 5 November 2026, Halozyme Therapeutics, Inc. (HALO) trades at a P/E ratio of 29.5×. Over the past ten years it has ranged from 0.0× (September 2020) to 242× (December 2020); the current reading is higher than 80% of that period. That is above the Biotechnology industry median of 10.3× and above the Healthcare sector median of 25.2×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/HALO/pe-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Halozyme Therapeutics, Inc. P/E ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/HALO/metrics/pe-ratio">Halozyme Therapeutics, Inc. (HALO) P/E ratio — stockrow.com</a></p>

Period	P/E ratio	Change
FY2025	25.8×	88.77%
FY2024	13.7×	(21.82%)
FY2023	17.5×	(53.10%)
FY2022	37.3×	164.02%
FY2021	14.1×	(68.29%)
FY2020	44.5×	—
FY2019	0.0×	—
FY2018	0.0×	—
FY2017	50.5×	—
FY2016	0.0×	—

Period	P/E ratio	Change
Sep 2026	26.3×	18.21%
Jun 2026	22.2×	0.46%
Mar 2026	22.1×	(14.16%)
Dec 2025	25.8×	71.93%
43 more quarters	Free account

Against its own ten years

Low 0.0× High 242×

Ten-year median 14.5×

Current reading's percentile 67

Company	P/E ratio
KYMR Kymera Therapeutics, Inc. compare	n/m
BMRN BioMarin Pharmaceutical Inc. compare	n/m
SMMT Summit Therapeutics PLC compare	n/m
BBIO BridgeBio Pharma, Inc. compare	n/m
ASND Ascendis Pharma A/S compare	18.3×
EXEL Exelixis, Inc. compare	19.9×
HALO Halozyme Therapeutics, Inc.	29.5×
TECH Bio-Techne Corp compare	62.2×
JAZZ Jazz Pharmaceuticals PLC compare	62.6×
Biotechnology industry median	10.3×
Healthcare sector median	25.2×
Market median	17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

Halozyme Therapeutics, Inc. (HALO) P/E ratio

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on HALO

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on HALO

Stockrow Weekly